Literature DB >> 23355910

Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?

Yusuf Yilmaz1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is generally considered as the hepatic manifestation of the metabolic syndrome (MS). Although there is no doubt that NAFLD is tightly linked to the MS, the diagnosis of NAFLD encompasses a broad range of histological entities and as a composite phenotype may be hindering attempts to understand the mechanistic basis of these variants. The awareness that NAFLD is not solely and invariably associated with the MS is a useful means to help direct future studies. We should be aware that mechanisms other than insulin resistance may contribute to the chronic inflammatory processes that underpin the development of liver fat accumulation and the subsequent architectural distortion of the liver. Further studies with special focus on hemoglobin as a risk factor for the development of NAFLD in the absence of MS should be performed.

Entities:  

Keywords:  Fibrosis; Hemoglobin; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease

Year:  2012        PMID: 23355910      PMCID: PMC3554796          DOI: 10.4254/wjh.v4.i12.332

Source DB:  PubMed          Journal:  World J Hepatol


  22 in total

1.  Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study.

Authors:  L Xu; C-F Xu; C-H Yu; M Miao; Y-M Li
Journal:  Gut       Date:  2009-12       Impact factor: 23.059

Review 2.  Redox reactions of hemoglobin and myoglobin: biological and toxicological implications.

Authors:  A I Alayash; R P Patel; R E Cashon
Journal:  Antioxid Redox Signal       Date:  2001-04       Impact factor: 8.401

Review 3.  NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression?

Authors:  Yusuf Yilmaz
Journal:  Semin Liver Dis       Date:  2012-03-13       Impact factor: 6.115

Review 4.  Iron overload: consequences, assessment, and monitoring.

Authors:  Ali T Taher; Khaled M Musallam; Adlette Inati
Journal:  Hemoglobin       Date:  2009       Impact factor: 0.849

Review 5.  Ten putative contributors to the obesity epidemic.

Authors:  Emily J McAllister; Nikhil V Dhurandhar; Scott W Keith; Louis J Aronne; Jamie Barger; Monica Baskin; Ruth M Benca; Joseph Biggio; Mary M Boggiano; Joe C Eisenmann; Mai Elobeid; Kevin R Fontaine; Peter Gluckman; Erin C Hanlon; Peter Katzmarzyk; Angelo Pietrobelli; David T Redden; Douglas M Ruden; Chenxi Wang; Robert A Waterland; Suzanne M Wright; David B Allison
Journal:  Crit Rev Food Sci Nutr       Date:  2009-11       Impact factor: 11.176

Review 6.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

7.  Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis.

Authors:  Tung-Ming Leung; George L Tipoe; Emily C Liong; Thomas Y H Lau; Man-Lung Fung; Amin A Nanji
Journal:  Int J Exp Pathol       Date:  2008-04-21       Impact factor: 1.925

Review 8.  Hyperviscosity in polycythemia vera and other red cell abnormalities.

Authors:  Hau C Kwaan; Jun Wang
Journal:  Semin Thromb Hemost       Date:  2003-10       Impact factor: 4.180

9.  Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery.

Authors:  V Trak-Smayra; D Dargere; R Noun; M Albuquerque; C Yaghi; M-H Gannagé-Yared; P Bedossa; V Paradis
Journal:  Gut       Date:  2008-04-10       Impact factor: 23.059

Review 10.  Prevention and treatment of the metabolic syndrome.

Authors:  S S Daskalopoulou; D P Mikhailidis; M Elisaf
Journal:  Angiology       Date:  2004 Nov-Dec       Impact factor: 3.619

View more
  10 in total

1.  Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.

Authors:  Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco
Journal:  Intern Emerg Med       Date:  2015-11-24       Impact factor: 3.397

2.  Non-alcoholic fatty liver disease in patients with migraine.

Authors:  Asuman Celikbilek; Mehmet Celikbilek; Aylin Okur; Serkan Dogan; Elif Borekci; Mustafa Kozan; Sebnem Gursoy
Journal:  Neurol Sci       Date:  2014-04-23       Impact factor: 3.307

Review 3.  Consensus statement on management of dyslipidemia in Indian subjects.

Authors:  K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati
Journal:  Indian Heart J       Date:  2014-12-24

4.  Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.

Authors:  Young Eun Chon; Kyu Sik Jung; Kwang Joon Kim; Dong Jin Joo; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2014-08-14       Impact factor: 3.199

5.  Circulating microRNAs in patients with non-alcoholic fatty liver disease.

Authors:  Mehmet Celikbilek; Mevlut Baskol; Serpil Taheri; Kemal Deniz; Serkan Dogan; Gokmen Zararsiz; Sebnem Gursoy; Kadri Guven; Omer Ozbakır; Munis Dundar; Mehmet Yucesoy
Journal:  World J Hepatol       Date:  2014-08-27

6.  Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Authors:  Amandeep Singh; Amaninder S Dhaliwal; Shailainder Singh; Atul Kumar; Rocio Lopez; Mohit Gupta; Mazen Noureddin; William Carey; Arthur McCullough; Naim Alkhouri
Journal:  Dig Dis Sci       Date:  2019-06-11       Impact factor: 3.199

Review 7.  Non-alcoholic fatty liver disease: A growing public health problem in Turkey.

Authors:  Eda Kaya; Yusuf Yılmaz
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

Review 8.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  Rare leptin in non-alcoholic fatty liver cirrhosis: A case report.

Authors:  Yao-Bin Nong; Hong-Na Huang; Jing-Jing Huang; Yuan-Qin Du; Wen-Xuan Song; De-Wen Mao; Yue-Xue Zhong; Rong-Huo Zhu; Xi-Yu Xiao; Rui-Xi Zhong
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

10.  Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD.

Authors:  Vanda Marques; Marta B Afonso; Nina Bierig; Filipa Duarte-Ramos; Álvaro Santos-Laso; Raul Jimenez-Agüero; Emma Eizaguirre; Luis Bujanda; Maria J Pareja; Rita Luís; Adília Costa; Mariana V Machado; Cristina Alonso; Enara Arretxe; José M Alustiza; Marcin Krawczyk; Frank Lammert; Dina G Tiniakos; Bertram Flehmig; Helena Cortez-Pinto; Jesus M Banales; Rui E Castro; Andrea Normann; Cecília M P Rodrigues
Journal:  Front Med (Lausanne)       Date:  2021-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.